Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec and Elan are evaluating the effectiveness of Tysabri in treating secondary-progressive multiple sclerosis (SPMS) in a global Phase 3b study.
Subscribe to our email newsletter
A Study to Characterise the Efficacy of Natalizumab on Disability (ASCEND) trial is a double-blind placebo-controlled study in which SPMS patients are randomised to receive either Tysabri 300 mg or placebo intravenously every four weeks for 96 weeks.
The ASCEND study is part of the collaboration between Biogen Idec and Elan to improve the well-being of patients with multiple sclerosis.
In the trial, the primary endpoint is to investigate whether treatment with Tysabri slows the accumulation of disability not related to relapses in subjects with SPMS.